About Aphios
Aphios is a company based in Boston (United States) founded in 1993. Aphios offers products and services including Zindol, APH-0701, nanoHYP, and Xantol. Aphios operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter Boston, United States
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aphios Pharma Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$504.73 K (USD), Grant
Sep 25, 2024
-
Investors
Citizens Bank
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aphios
Aphios offers a comprehensive portfolio of products and services, including Zindol, APH-0701, nanoHYP, and Xantol.
Oncology treatment using nanotechnology for cancer management.
Oncology-focused drug in development pipeline.
Infectious disease treatment targeting HIV and influenza.
CNS disorder therapy for conditions like Alzheimer's.
People of Aphios
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aphios
Investors in Aphios
Aphios has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Citizens Bank, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Federal innovation and scientific achievement services are provided.
|
Locked | Locked | Locked | |
|
Commercial banking services are provided to individuals and businesses.
|
Locked | Locked | Locked |
Investor details for Aphios
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aphios
Investment portfolio details for Aphios
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aphios
Detailed financials for Aphios
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aphios Comparisons
Peer comparison for Aphios
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aphios
Aphios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Aphios
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aphios
Complete news archive for Aphios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aphios
Aphios was founded in 1993 and raised its 1st funding round 15 years after it was founded.
Aphios is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Founded in 1993 and based in Boston, United States, therapeutics are developed by the company for cancer treatment, supportive care, infectious diseases including HIV, influenza, and coronavirus, as well as central and peripheral nervous system disorders such as Alzheimers disease, multiple sclerosis, pain, and addiction. Operations focus on pharmaceutical innovation in the biotechnology sector. The lead compound, Zindol, an enhanced ginger product, targets chemotherapy-induced nausea and vomiting.
Aphios's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Aphios offers Zindol, APH-0701, nanoHYP, and Xantol.
Aphios has 5 investors. Key investors include Citizens Bank, NIH, HHS, SBIR, and National Heart, Lung, and Blood Institute.